{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Papasavvas E"],"funding":["NIAID NIH HHS","NCI NIH HHS"],"pagination":["2051-2054"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8416745"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(12)"],"pubmed_abstract":["We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels."],"journal":["AIDS (London, England)"],"pubmed_title":["Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption."],"pmcid":["PMC8416745"],"funding_grant_id":["UM1 AI126620","U01 AI110434","P30 AI045008","P30 CA010815"],"pubmed_authors":["Papasavvas E","Kostman JR","Tebas P","Azzoni L","Howell BJ","Fair M","Montaner LJ","Hazuda DJ","Mounzer K","Ross BN"],"additional_accession":[]},"is_claimable":false,"name":"Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.","description":"We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-22T21:49:17.982Z","creation":"2025-02-19T01:27:36.3Z"},"accession":"S-EPMC8416745","cross_references":{"pubmed":["34049356"],"doi":["10.1097/qad.0000000000002961","10.1097/QAD.0000000000002961"]}}